Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia

To date there is no resolutive cure for FA; however, the FDA has recently approved omaveloxolone - a potent activator of nuclear factor erythroid 2-related factor 2 (NRF2) - as the first treatment for FA. This review discusses the urgency to find a resolutive cure for neurodegenerative diseases that will most probably be achieved via combinatorial therapy targeting multiple disease pathways, and how omavaloxolone serves as an example for future treatments.

Read More Here